{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:21:46Z","timestamp":1758637306362},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1007\/bf03345277","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T05:51:15Z","timestamp":1396072275000},"page":"272-280","source":"Crossref","is-referenced-by-count":17,"title":["Novel aspects of immunosuppressive and radiotherapy management of Graves\u2019 ophthalmopathy"],"prefix":"10.1007","volume":"27","author":[{"given":"Claudio","family":"Marcocci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Menconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pinchera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,18]]},"reference":[{"key":"BF03345277_CR1","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C. Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168\u201399.","journal-title":"Endocr Rev"},{"key":"BF03345277_CR2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/thy.1997.7.885","volume":"7","author":"MN Gerding","year":"1997","unstructured":"Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves\u2019 ophthalmopathy is markedly decreased: measurement by the Medical Outcomes Study Instrument. Thyroid 1997, 7: 885\u20139.","journal-title":"Thyroid"},{"key":"BF03345277_CR3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1530\/eje.0.1440311","volume":"144","author":"GE Krassas","year":"2001","unstructured":"Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001, 144: 311\u20138.","journal-title":"Eur J Endocrinol"},{"key":"BF03345277_CR4","first-page":"3562","volume":"86","author":"C Marcocci","year":"2001","unstructured":"Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous and oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001, 86: 3562\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR5","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1089\/thy.2000.10.521","volume":"10","author":"M Weissel","year":"2000","unstructured":"Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000, 10: 521.","journal-title":"Thyroid"},{"key":"BF03345277_CR6","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1210\/jcem.79.6.7989493","volume":"79","author":"PTE Postema","year":"1994","unstructured":"Postema PTE, Krenning EP, Wijngaarde R, et al. (111In-DTPAD- Phe1) octreotide scintigraphy in thyroidal and orbital Graves\u2019 disease: a parameter of disease activity. J Clin Endocrinol Metab 1994, 79: 1845\u201351.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1089\/thy.1995.5.107","volume":"5","author":"G Kahaly","year":"1995","unstructured":"Kahaly G, Diaz M, Just M, Beyer J, Lieb W. Role of octreoscan and correlation with MR imaging in Graves\u2019 ophthalmopathy. Thyroid 1995, 5: 107\u201311.","journal-title":"Thyroid"},{"key":"BF03345277_CR8","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2265.1995.tb02682.x","volume":"42","author":"KE Krassas","year":"1995","unstructured":"Krassas KE, Dumas A, Pontikides N, Kaltsas T. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease. Clin Endocrinol (Oxf) 1995, 42: 571\u201380.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03345277_CR9","first-page":"3790","volume":"83","author":"A Colao","year":"1998","unstructured":"Colao A, Lastoria S, Ferone D, et al. Orbital scintigraphy with [111In-diethylenetriamine pentaacetic acid-D-Phe-1]- octreotide predicts the clinical response to corticosteroid therapy in patients with Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 1998, 83: 3790\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR10","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1210\/jc.2002-020790","volume":"87","author":"D Pasquali","year":"2002","unstructured":"Pasquali D, Notaro A, Bonavolont\u00e0 G, Vassallo P, Bellastella A, Sinisi AA. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves\u2019 disease. J Clin Endocrinol Metab 2002, 87: 5125\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/bmj.304.6820.158","volume":"304","author":"TC Chang","year":"1992","unstructured":"Chang TC, Kao SCS, Huang KM. Octreotide and Graves\u2019 ophthalmopathy and pretibial mixedema. Br Med J 1992, 304: 158.","journal-title":"Br Med J"},{"key":"BF03345277_CR12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/thy.1996.6.381","volume":"6","author":"AVC Kung","year":"1996","unstructured":"Kung AVC, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroids in the treatment of Graves\u2019 ophthalmopathy. Thyroid 1996, 6: 381\u20134.","journal-title":"Thyroid"},{"key":"BF03345277_CR13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1530\/eje.0.1360416","volume":"136","author":"GE Krassas","year":"1997","unstructured":"Krassas GE, Kaltsas T, Dumas A, Pontikides N, Tolis G. Lanreotide in the treatment of patients with thyroid eye disease. Eur J Endocrinol 1997, 136: 416\u201322.","journal-title":"Eur J Endocrinol"},{"key":"BF03345277_CR14","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1001\/jama.1995.03520470073035","volume":"273","author":"TA Ratko","year":"1995","unstructured":"Ratko TA, Burnett DA, Foulke GE and the University Hospital Consortium Expert Panel for Off-Label use of polyvalent Intravenously administered Immunoglobulin Preparation. Recommendations for off-label use of intravenously administered immunoglobulin preparation. JAMA 1995, 273: 1865\u201370.","journal-title":"JAMA"},{"key":"BF03345277_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/acta.0.1260013","volume":"126","author":"A Antonelli","year":"1992","unstructured":"Antonelli A, Saracino A, Alberti B, et al. High-dose intravenous immunoglobulin treatment in Graves\u2019 ophthalmopathy. Acta Endocrinol (Copenh) 1992, 126: 13\u201323.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"BF03345277_CR16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/thy.1997.7.579","volume":"7","author":"L Baschieri","year":"1997","unstructured":"Baschieri L, Antonelli A, Nardi S, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves\u2019 ophthalmopathy. Thyroid 1997, 7: 579\u201385.","journal-title":"Thyroid"},{"key":"BF03345277_CR17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","volume":"106","author":"G Kahaly","year":"1996","unstructured":"Kahaly G, Pitz S, Muller-Forrell W, Hommel G. Randomized trial of intravenous immunoglobulin versus prednisolone in Graves\u2019 ophthalmopathy. Clin Exp Immunol 1996, 106: 197\u2013202.","journal-title":"Clin Exp Immunol"},{"issue":"Suppl15","key":"BF03345277_CR18","first-page":"S109","volume":"14","author":"T Seppel","year":"1996","unstructured":"Seppel T, Schlaghecke R, Becker A, Engelbrecht C, Feldkamp J, Kornely E. High-dose intravenous therapy with 7S immunoglobulins in autoimmune endocrine ophthalmopathy. Clin Exp Immunol 1996, 14 (Suppl 15): S109\u201314.","journal-title":"Clin Exp Immunol"},{"key":"BF03345277_CR19","first-page":"501","volume":"86","author":"WM Wiersinga","year":"2001","unstructured":"Wiersinga WM, Prummel MF. Pathogenesis of Graves\u2019 ophthalmopathy-Current understanding. J Clin Endocrinol Metab 2001, 86: 501\u20133.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR20","first-page":"1120","volume":"77","author":"MM Carli De","year":"1993","unstructured":"De Carli MM, Mariotti S, Marcocci C, et al. Cytolytic T cells withTh1-like profile predominate in retroorbital lymphocytic infiltrates of Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 1993, 77: 1120\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR21","first-page":"287","volume":"1","author":"RS Bahn","year":"1996","unstructured":"Bahn RS. Graves\u2019 ophthalmopathy: the role of cytokines in pathogenesis. In: Grass GH and Kaplan HM eds. Handbook of Endocrinology. 2nd ed. vol 1. Boca Rato: CRC Press. 1996, 287\u201395.","journal-title":"Handbook of Endocrinology"},{"key":"BF03345277_CR22","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1210\/jcem-72-5-1169","volume":"72","author":"TJ Smith","year":"1991","unstructured":"Smith TJ, Bahn RS, Gorman CA, Cheavens M. Stimulation of glycosaminoglycan accumulation by interferon \u03b2 in cultured retroocular fibroblasts. J Clin Endocrinol Metab 1991, 72: 1169\u201371.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR23","first-page":"446","volume":"81","author":"L Bartalena","year":"1996","unstructured":"Bartalena L, Marcocci C, Pinchera A. Cytokine antagonists: new ideas for the management of Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 1996, 81: 446\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1097-0029(20000801)50:3<229::AID-JEMT6>3.0.CO;2-H","volume":"50","author":"A Raza","year":"2000","unstructured":"Raza A. Anti-TNF therapies in rheumatoid arthritis, Chron\u2019s disease, sepsis, and myelodisplastic syndrome. Micr Res Techn 2000, 50: 229\u201335.","journal-title":"Micr Res Techn"},{"key":"BF03345277_CR25","first-page":"449","volume":"81","author":"GH Tan","year":"1996","unstructured":"Tan GH, Dutton CM, Bahn RS. Interleukin-1 (IL-1) receptor antagonists and soluble IL-1 receptor inhibit IL-1-induced glycosamimoglycans production in cultured human orbital fibroblasts from patients with Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 1996, 81: 449\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR26","first-page":"2244","volume":"82","author":"LC Hofbauer","year":"1997","unstructured":"Hofbauer LC, Muglberg T, Konig A, Heufelder G, Schworm H-D, Heufelder AE. Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves\u2019 ophthalmopathy undergoing orbital radiotherapy. J Clin Endocrinol Metab 1997, 82: 2244\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1530\/eje.0.1430197","volume":"143","author":"M Salvi","year":"2000","unstructured":"Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentration of proinflammatory cytokines in Graves\u2019 disease: effect of thyroid function, ophthalmopathy and sigarette smoking. Eur J Endocrinol 2000, 143. 197\u2013202.","journal-title":"Eur J Endocrinol"},{"key":"BF03345277_CR28","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1046\/j.1365-2265.2000.00988.x","volume":"52","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Manetti L, Tanda ML, et al. Soluble interleukin receptor antagonist concentration is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids. Clin Endocrinol (Oxf) 2000, 52: 647\u201351.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"BF03345277_CR29","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jcem.82.6.9995","volume":"82","author":"C Balazs","year":"1998","unstructured":"Balazs C, Kiss E, Vamos A, Molnar I, Farid NR. Beneficial effect of pentoxyfilline on thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 1998; 82: 1999\u20132002.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1530\/acta.0.1290322","volume":"129","author":"C-C Chang","year":"1993","unstructured":"Chang C-C, Chang T-C, Kao SCS, Kuo Y-F, Chien L-F. Pentoxifylline inhibits the proliferation and glycosaminoglycan synthesis of cultured fibroblasts derived from patients with Graves\u2019 ophthalmopathy and pretibial myxoedema. Acta Endocrinol (Copenh) 1993, 129: 322\u20137.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"BF03345277_CR31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-2007-978919","volume":"30","author":"C Balazs","year":"1998","unstructured":"Balazs C, Kiss H, Farid NR. Inhibitory effect of pentoxifylline on HLA-DR expression and glycosaminoglycan synthesis by retrobulbar fibroblasts. Horm Metab Res 1998, 30: 496\u20139.","journal-title":"Horm Metab Res"},{"key":"BF03345277_CR32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1006\/abbi.1994.1475","volume":"315","author":"DR Doerge","year":"1994","unstructured":"Doerge DR, Taurog A, Dorris M. Evidence for a radical mechanism in peroxidase-catalyzed coupling. I. Steadystate experiments with various peroxidases. Arch Biochem Biophys 1994, 315: 82\u20139.","journal-title":"Arch Biochem Biophys"},{"key":"BF03345277_CR33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1677\/joe.0.1550151","volume":"155","author":"P Venditti","year":"1997","unstructured":"Venditti P, Balestrieri M, Di Meo S, De Leo T. Effect of thyroid state on lipid peroxidation, antioxidantd defences, and susceptibility to oxidative stress in rat tissues. J Endocrinol 1997, 155: 151\u20137.","journal-title":"J Endocrinol"},{"key":"BF03345277_CR34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jcem.83.1.4478","volume":"83","author":"Y Hiromatsu","year":"1998","unstructured":"Hiromatsu Y, Yang D, Miyake I, et al. Nicotinamide decreases cytokine-induced activation of orbital fibroblasts from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 1998, 83: 121\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR35","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0002-9394(00)00359-7","volume":"129","author":"EA Bouzas","year":"2000","unstructured":"Bouzas EA, Karadimas P, Mastrorakos G, Koutras DA. Antioxidant agents in the treatment of Graves\u2019 ophthalmopathy. Am J Ophthalmol 2000, 129: 618\u201322.","journal-title":"Am J Ophthalmol"},{"key":"BF03345277_CR36","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF03347329","volume":"21","author":"C Marcocci","year":"1998","unstructured":"Marcocci, C, Bartalena, L, Pinchera, A. Ablative or non-ablative therapy for Graves\u2019 hyperthyroidism in patients with ophthalmopathy? J Endocrinol Invest 1998, 21: 468\u201371.","journal-title":"J Endocrinol Invest"},{"key":"BF03345277_CR37","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/0002-9610(69)90151-2","volume":"118","author":"B Catz","year":"1969","unstructured":"Catz B, Perzik SL. Total thyroidectomy in the management of thyrotoxic and euthyroid Graves\u2019 disease. Am J Surg 1969, 118: 434\u20139.","journal-title":"Am J Surg"},{"key":"BF03345277_CR38","first-page":"187","volume-title":"Orbit","author":"LJ DeGroot","year":"1996","unstructured":"DeGroot LJ. Evaluation of thyroid ablative therapy for ophthalmopathy of Graves\u2019 disease. Orbit 1996, 187\u201396."},{"key":"BF03345277_CR39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/095530098141500","volume":"74","author":"G Hildebrandt","year":"1998","unstructured":"Hildebrandt G, Seed MP, Freemantle CN, Alan CAS, Colville-Nash PR, Trott KR. Mechanisms of the anti-infiammatory activity of low-dose radiation therapy. Int J Radiat Biol 1998, 74: 367\u201378.","journal-title":"Int J Radiat Biol"},{"key":"BF03345277_CR40","first-page":"102","volume":"85","author":"G Kahaly","year":"2000","unstructured":"Kahaly G, Roesler HP, Pitz S, Hommel G. Low- versus high-dose radiotherapy for Graves\u2019 ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000, 85: 102\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR41","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","volume":"355","author":"MP Mourits","year":"2000","unstructured":"Mourits MP, van Kempen-Harteveld, Garcia MBG, Koppeschaar HPF, Tick L, Terwee CB. Radiotherapy for Graves\u2019 orbitopathy: randomised placebo-controlled study. Lancet 2000, 355: 1505\u20139.","journal-title":"Lancet"},{"key":"BF03345277_CR42","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0161-6420(01)00632-7","volume":"108","author":"CA Gorman","year":"2001","unstructured":"Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves\u2019 ophthalmopathy. Ophthalmology 2001, 108: 1523\u20134.","journal-title":"Ophthalmology"},{"key":"BF03345277_CR43","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/S0161-6420(02)01293-9","volume":"109","author":"CA Gorman","year":"2002","unstructured":"Gorman CA, Garrity JA, Fatourechi V, et al. The aftermath of orbital radiotherapy for Graves\u2019 ophthalmopathy. Ophthalmology 2002, 109: 2100\u20137.","journal-title":"Ophthalmology"},{"key":"BF03345277_CR44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF03345116","volume":"26","author":"L Bartalena","year":"2003","unstructured":"Bartalena L, Marcocci C, Gorman CA, Wiersinga WM, Pinchera A. Orbital radiotherapy for Graves\u2019 ophthalmopathy: Useful or useless? Safe or dangerous. J Endocrinol Invest 2003, 26: 5\u201316","journal-title":"J Endocrinol Invest"},{"key":"BF03345277_CR45","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/00002341-200211000-00003","volume":"18","author":"C Marcocci","year":"2002","unstructured":"Marcocci C, Bartalena L, Marin\u00f2 M, et al. Current medical management of Graves\u2019 ophthalmopahy. Ophthal Plast Reconstr Surg 2002, 18: 402\u20138.","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"BF03345277_CR46","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2003-030260","volume":"88","author":"C Marcocci","year":"2003","unstructured":"Marcocci C, Bartalena L, Rocchi R, et al. Long term safety of orbital radiotherapy for Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 2003, 88: 3561\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"BF03345277_CR47","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/BF03344027","volume":"25","author":"L Bartalena","year":"2002","unstructured":"Bartalena L. Smoking and Graves\u2019 disease. J Endocrinol Invest 2002, 25: 402.","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03345277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03345277\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03345277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T21:57:35Z","timestamp":1565301455000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03345277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["BF03345277"],"URL":"https:\/\/doi.org\/10.1007\/bf03345277","relation":{},"ISSN":["0391-4097","1720-8386"],"issn-type":[{"value":"0391-4097","type":"print"},{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}